Sarepta advances following inclusion in Vertex presentation
Sarepta Therapeutics' (SRPT) stock is climbing after Vertex Pharmaceuticals (VRTX) included in-depth information about Sarepta's treatment for Duchenne Muscular Dystrophy, or DMD, in a slide presentation. In the slide presentation, which was posted online, Vertex describes how Sarepta's treatment, called Eteplirsen, works. The drug has "demonstrated a broadly favorable safety and tolerability profile and restoration of dystrophin protein expression," Vertex added. Although a number of drugs made by several other companies are mentioned by Vertex on a previous slide, the information provided about Sarepta's treatment is far more comprehensive than the details provided for the alternati ve drugs. This development led to speculation among some investors that Vertex could be interested in buying rights to the treatment outside of North America from Sarepta. In late morning trading, Sarepta rose 61c, or 2.12%, to $29.36.
great point gary that we all had forgotten; i reviewed posts around that time frame; concensus here was it had something to do with forumulation and the marberg contract
timing is suspect
confidential treatment filing on nov 16, 2 weeks later vrtx mentions srpt extensively in presentation
maybe, maybe not
one more piece to the puzzle i forgot about
Sentiment: Strong Buy
There are other reasons for VRTX and SRPT to be natural partners. Several years ago, SRPT was testing an HCV treatment based on their unique technologies. It didn't go anywhere. My impression was that they let it languish because of all the expense and difficulty of getting by the FDA. VRTX was the main competitor for HCV back then and their treatment went on to be a big money maker, but SRPT's treatment was better. Several years further work have made SRPT more creditable Maybe VRTX might want to revive the dormant HCV effort and become its champion moving forward in some collaborative manner.
I don't remember it that way, at all. AVI's HCV's drug was a failure. It was the PMO, just like Eteplirsen, only adjusted for the HCV virus. The big problem was that the liver of HCV patients is terribly scarred. The PMO couldn't get in. Therefore, the PMO did not reach the virus. With Duchenne, the PMO can get into the leaky muscle cells. Having said that, AVI (now Sarepta) has significantly advanced its chemistry. We now know that preclinical work using PMO+ against several different viruses has produced great results. One of those PMO+ drugs is now in the human clinic for treatment of Marburg virus infection. However, there have been no reports from the company about starting up new studies for an HCV therapeutic. Yet.
more speculation. yawwwwwwwwwwwwwwwwwwwwwwn. i heard bigfoot exists cuz i saw this video thu uther day of sumthing big n black in thu woodz, of course it could've just been a bear.
You are correct, it was not bigfoot it was a bear. I have bears in my yard a couple days every week, being out here in the cascades foothills.They come by and eat my garbage out of the compost pile. There are elk, deer,foxes,coyotes, bobcats and even moutain lions as well. But let's be clear, there are bears here in the market as well, and the goal is to in fact shoot and kill them, and eat the stinking carcass.
It takes bulls and bears and there are winners and there are losers. You Johnny nickels have made your choice as a bear. I zeroed my scope a while back maybe I should check it again for this winters hunt.